163.62+0.93+0.57%
02:42:26 PMBTT
Plus500. 80% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Tuesday morning 07/02/2024 the Procter & Gamble Co. share started trading at the price of $162.59.Compared to the closing price on Monday 07/01/2024 on BTT of $162.69, this is a drop of 0.06%.There are 2.36 B shares outstanding in Procter & Gamble Co., which values the company at $389.49 B.
Is Procter & Gamble stock a Buy, Sell or Hold?
Procter & Gamble stock has received a consensus rating of buy. The average rating score is Aa3 and is based on 60 buy ratings, 10 hold ratings, and 0 sell ratings.What was the 52-week low for Procter & Gamble stock?
The low in the last 52 weeks of Procter & Gamble stock was 141.47. According to the current price, Procter & Gamble is 115.66% away from the 52-week low.What was the 52-week high for Procter & Gamble stock?
The high in the last 52 weeks of Procter & Gamble stock was 169.41. According to the current price, Procter & Gamble is 96.58% away from the 52-week high.What are analysts forecasts for Procter & Gamble stock?
The 70 analysts offering price forecasts for Procter & Gamble have a median target of 163.91, with a high estimate of 187.00 and a low estimate of 130.00. The median estimate represents a 99.82 difference from the last price of 163.62.Procter Gamble Stock Snapshot
163.61
Bid
18.00
Bid Size
163.63
Ask
11.00
Ask Size
7/2/2024
Date
2:42 PM
Time
131,102.00
Volume
162.69
Prev. Close
162.59
Open
389.09 B
Market Cap in USD
2.36 B
Number of Shares
161.72
Day Low
163.80
Day High
163.62
141.47
52 Week Low
169.41
52 Week High
163.62
3.68
Dividend in USD
2.43
Dividend Yield
25.72
P/E Ratio
99.94
Free Float in %
6.07
EPS in USD
19.46
Book Value per Share in USD
6.78
Cash Flow per Share in USD
Procter & Gamble NewsMore News
InvestorPlace
Seeking Safety? 3 Must-Buy Stocks for Your Retirement Portfolio.
InvestorPlace
Supreme Rulers: 3 Dividend Kings to Buy Before Wall Street Takes Notice
Benzinga
InvestorPlace
Dow 30,000? Buy These 3 Stocks Now for the Coming Dow Crash
InvestorPlace
The 3 Most Undervalued Blue-Chip Stocks to Buy in June 2024
Historical Prices for Procter & Gamble
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Procter & Gamble Analyst Data
Total Analysts: 70
Buy Ratings: 60 Neutral Ratings: 10 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 130.00 Median: 163.91 Highest: 187.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Procter & Gamble Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/24/24 | Exane BNP Paribas | Maintained Buy | $187 | gut | ||
| 04/25/24 | Argus Research Company | Maintained Buy | $185 | gut | ||
| 04/23/24 | Barclays Capital | Maintained Buy | $170 | gut | ||
| 04/22/24 | Deutsche Bank | Maintained Buy | $171 | gut | ||
| 04/22/24 | Jefferies & Company Inc. | Maintained Buy | $182 | gut | ||
| 04/12/24 | Barclays Capital | Maintained Buy | $168 | gut | ||
| 04/03/24 | Deutsche Bank | Maintained Buy | $172 | gut | ||
| 03/01/24 | Goldman Sachs | Maintained Hold | $168 | neutral | ||
| 01/25/24 | Barclays Capital | Maintained Buy | $165 | gut | ||
| 01/24/24 | RBC Capital Markets | Maintained Hold | $157 | neutral | ||
| 01/24/24 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $157 | gut | ||
| 01/24/24 | UBS | Maintained Buy | $178 | gut | ||
| 01/24/24 | Wells Fargo & Co | Maintained Buy | $170 | gut | ||
| 01/24/24 | Raymond James Financial, Inc. | Maintained Buy | $175 | gut | ||
| 01/18/24 | J.P. Morgan | Maintained Buy | $162 | gut | ||
| 01/16/24 | Barclays Capital | Maintained Buy | $160 | gut | ||
| 11/13/23 | Jefferies & Company Inc. | Maintained Buy | $177 | gut | ||
| 10/20/23 | DZ BANK | Upgraded to Buy | $155 | gut | ||
| 10/19/23 | Wells Fargo & Co | Maintained Buy | $162 | gut | ||
| 10/19/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $155 | gut | ||
| 10/16/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $151 | gut | ||
| 10/12/23 | Barclays Capital | Maintained Buy | $154 | gut | ||
| 10/12/23 | J.P. Morgan | Maintained Buy | $169 | gut | ||
| 10/12/23 | Bernstein | Maintained Hold | $153 | neutral | ||
| 09/22/23 | HSBC | Maintained Buy | $179 | gut | ||
| 09/08/23 | William Blair | Maintained Hold | neutral | |||
| 08/01/23 | Morgan Stanley | Maintained Buy | $174 | gut | ||
| 08/01/23 | Bank of America Merrill Lynch | Maintained Buy | $175 | gut | ||
| 08/01/23 | Barclays Capital | Maintained Buy | $166 | gut | ||
| 07/31/23 | RBC Capital Markets | Maintained Hold | $167 | neutral | ||
| 07/31/23 | Wells Fargo & Co | Maintained Buy | $170 | gut | ||
| 07/31/23 | Deutsche Bank | Maintained Buy | $173 | gut | ||
| 07/25/23 | Morgan Stanley | Maintained Buy | $174 | gut | ||
| 07/20/23 | Barclays Capital | Maintained Buy | $160 | gut | ||
| 07/11/23 | Citigroup Corp. | Maintained Buy | $177 | gut | ||
| 04/26/23 | Barclays Capital | Maintained Buy | $167 | gut | ||
| 04/24/23 | Citigroup Corp. | Maintained Buy | $177 | gut | ||
| 04/24/23 | Evercore | Maintained Buy | $170 | gut | ||
| 04/24/23 | Jefferies & Company Inc. | Maintained Buy | $175 | gut | ||
| 04/24/23 | Raymond James Financial, Inc. | Maintained Buy | $175 | gut | ||
| 04/24/23 | RBC Capital Markets | Maintained Hold | $165 | neutral | ||
| 04/24/23 | Morgan Stanley | Maintained Buy | $174 | gut | ||
| 04/24/23 | UBS | Maintained Buy | $180 | gut | ||
| 04/14/23 | Barclays Capital | Maintained Buy | $160 | gut | ||
| 04/06/23 | UBS | Maintained Buy | $170 | gut | ||
| 03/20/23 | Deutsche Bank | Maintained Buy | $156 | gut | ||
| 03/03/23 | J.P. Morgan | Upgraded to Buy | $155 | gut | ||
| 03/01/23 | UBS | Upgraded to Buy | $163 | gut | ||
| 02/17/23 | Citigroup Corp. | Maintained Buy | $160 | gut | ||
| 01/23/23 | Barclays Capital | Maintained Buy | $158 | gut |
Procter & Gamble Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 84,335 | 87,167 | 89,744 | 94,531 | 97,535 |
| Dividend | 3.82 | 4.05 | 4.23 | 4.48 | 4.36 |
| Dividend Yield (in %) | 2.34 % | 2.49 % | 2.60 % | 2.75 % | 2.68 % |
| EPS | 6.55 | 6.97 | 7.46 | 8.02 | 8.21 |
| P/E Ratio | 24.86 | 23.37 | 21.82 | 20.31 | 19.83 |
| EBIT | 20,237 | 21,514 | 22,843 | 24,116 | 25,071 |
| EBITDA | 22,988 | 24,584 | 26,205 | 27,535 | 29,460 |
| Net Profit | 16,176 | 17,076 | 18,108 | 19,154 | 19,633 |
| Net Profit Adjusted | 16,130 | 17,093 | 18,154 | 19,332 | - |
| Pre-Tax Profit | 20,217 | 21,617 | 22,888 | 24,338 | 25,223 |
| Net Profit (Adjusted) | 19,730 | 21,548 | 22,887 | 23,827 | 25,223 |
| EPS (Non-GAAP) ex. SOE | 6.55 | 6.97 | 7.46 | 8.02 | 8.21 |
| EPS (GAAP) | 6.26 | 6.93 | 7.44 | 7.89 | 8.25 |
| Gross Income | 43,097 | 44,827 | 46,889 | 50,344 | - |
| Cash Flow from Investing | -3,694 | -3,603 | -3,725 | -4,751 | - |
| Cash Flow from Operations | 20,032 | 21,239 | 22,766 | 23,506 | - |
| Cash Flow from Financing | -16,347 | -14,744 | -15,310 | -22,829 | - |
| Cash Flow per Share | 7.47 | 7.93 | 8.57 | 8.29 | 10.15 |
| Free Cash Flow | 15,894 | 16,742 | 17,882 | 19,749 | - |
| Free Cash Flow per Share | 6.73 | 7.13 | 7.65 | - | - |
| Book Value per Share | 21.28 | 22.73 | 24.40 | 24.27 | 26.59 |
| Net Debt | 25,912 | 23,777 | 20,870 | 19,396 | 11,260 |
| Research & Development Exp. | 2,278 | 2,348 | 2,440 | - | - |
| Capital Expenditure | 3,431 | 3,710 | 3,830 | 3,748 | 4,292 |
| Selling, General & Admin. Exp. | 23,266 | 23,668 | 24,649 | 25,345 | - |
| Shareholder’s Equity | 51,001 | 53,534 | 56,594 | 59,936 | 64,633 |
| Total Assets | 118,065 | 121,972 | 126,668 | 109,269 | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 06/30/24 | Next Year ending 06/30/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 21 | 18 | 18 | 26 | 26 |
| Average Estimate | 1.373 USD | 1.938 USD | 1.972 USD | 6.550 USD | 6.968 USD |
| Year Ago | 1.402 USD | 1.886 USD | 1.441 USD | 6.068 USD | - |
| Publish Date | 7/30/2024 | 10/16/2024 | 1/22/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 18 | 13 | 13 | 24 | 24 |
| Average Estimate | 20,799 USD | 22,402 USD | 22,145 USD | 84,335 USD | 87,167 USD |
| Year Ago | 20,553 USD | 21,871 USD | 21,441 USD | 82,006 USD | - |
| Publish Date | 7/30/2024 | 10/16/2024 | 1/22/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 82,006.00 | 80,187.00 | 76,118.00 | 70,950.00 | 67,684.00 | 66,832.00 | 65,058.00 |
| Change of sales in % | 2.27 | 5.35 | 7.28 | 4.83 | 1.27 | 2.73 | -0.37 |
| Gross profit on sales | 39,406.00 | 38,212.00 | 39,144.00 | 36,314.00 | 33,437.00 | 33,383.00 | 33,116.00 |
| Gross profit on sales change in % | 3.12 | -2.38 | 7.79 | 8.60 | 0.16 | 0.81 | 0.02 |
| Operating income | 18,357.00 | 17,913.00 | 18,592.00 | 16,392.00 | 14,512.00 | 14,782.00 | 14,557.00 |
| Operating income change in % | 2.48 | -3.65 | 13.42 | 12.95 | -1.83 | 1.55 | -0.21 |
| Income before tax | 18,353.00 | 17,995.00 | 17,615.00 | 15,834.00 | 6,069.00 | 13,326.00 | 13,257.00 |
| Income before tax change in % | 1.99 | 2.16 | 11.25 | 160.90 | -54.46 | 0.52 | -0.84 |
| Income after tax | 14,653.00 | 14,742.00 | 14,306.00 | 13,027.00 | 3,897.00 | 9,750.00 | 9,991.00 |
| Income after tax change in % | -0.60 | 3.05 | 9.82 | 234.28 | -60.03 | -2.41 | -0.94 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 73,764.00 | 70,354.00 | 72,653.00 | 73,822.00 | 67,516.00 | 65,427.00 | 64,628.00 |
| Long-term liabilities per share | 16.09 | 15.57 | 16.27 | 16.47 | 14.99 | 14.89 | 13.48 |
| Equity | 47,065.00 | 46,854.00 | 46,654.00 | 46,878.00 | 47,579.00 | 52,883.00 | 55,778.00 |
| Equity change in % | 0.46 | 0.52 | -0.25 | -1.39 | -9.86 | -5.26 | -3.77 |
| Balance sheet total | 120,829.00 | 117,208.00 | 119,307.00 | 120,700.00 | 115,095.00 | 118,310.00 | 120,406.00 |
| Balance sheet total change in % | 3.09 | -1.76 | -1.15 | 4.87 | -2.72 | -1.74 | -5.29 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 33.02 | 31.58 | 29.26 | 27.02 | 26.65 | 25.16 | 23.74 |
| P/E ratio (year end quote, basic EPS) | 25.72 | 24.77 | 24.53 | 24.10 | 76.68 | 21.27 | 23.90 |
| P/E ratio (year end quote, diluted EPS) | 25.72 | 24.77 | 24.53 | 24.10 | 76.68 | 21.27 | 23.90 |
| P/E ratio (year end quote) | 25.72 | 24.77 | 24.53 | 24.10 | 76.68 | 21.27 | 23.90 |
| Dividend yield in % | 2.43 | 2.45 | 2.40 | 2.53 | 2.64 | 3.57 | 3.10 |
| Equity ratio in % | 38.04 | 39.03 | 38.14 | 37.80 | 40.20 | 43.38 | 45.00 |
| Debt ratio in % | 61.05 | 60.02 | 60.90 | 61.16 | 58.66 | 55.30 | 53.68 |
Procter & Gamble Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Kempczinski Christopher J | 06/10/2024 | 180.00 | 6,727.28 | n/a | Buy | No |
| Portman Robert Jones | 06/10/2024 | 45.00 | 1,790.92 | n/a | Buy | No |
| McCarthy Christine M | 06/10/2024 | 224.00 | 12,119.63 | n/a | Buy | No |
| Allen Bertrand Marc | 06/10/2024 | 180.00 | 7,528.94 | n/a | Buy | No |
| McEvoy Ashley | 06/10/2024 | 180.00 | 1,597.09 | n/a | Buy | No |
| WOERTZ PATRICIA A | 06/10/2024 | 180.00 | 47,828.98 | n/a | Buy | No |
| JIMENEZ JOSEPH | 06/10/2024 | 284.00 | 30,776.98 | n/a | Buy | No |
| LUNDGREN TERRY J | 06/10/2024 | 217.00 | 39,775.37 | n/a | Buy | No |
| Braly Angela F | 06/10/2024 | 165.00 | 57,977.79 | n/a | Buy | No |
| Biggs M. Brett | 06/10/2024 | 180.00 | 2,071.14 | n/a | Buy | No |
| Raman Sundar G. | 05/19/2024 | 31,924.00 | 19,041.70 | 166.95 | Sell | No |
| Raman Sundar G. | 05/19/2024 | 31,924.00 | 50,965.70 | 78.52 | Buy | No |
| Aguilar Moses Victor Javier | 05/15/2024 | 9,149.00 | 12,928.59 | 167.72 | Sell | No |
| Aguilar Moses Victor Javier | 05/15/2024 | 9,149.00 | 22,077.59 | 85.13 | Buy | No |
| Keith R. Alexandra | 05/14/2024 | 5,493.16 | 2,031.85 | 165.88 | Sell | No |
| Coombe Gary A | 05/06/2024 | 21,388.00 | 36,853.67 | 164.98 | Sell | No |
| Coombe Gary A | 05/06/2024 | 21,388.00 | 58,241.67 | 80.29 | Buy | No |
| Jejurikar Shailesh | 05/05/2024 | 31,859.00 | 9,738.91 | 164.90 | Sell | No |
| Jejurikar Shailesh | 05/05/2024 | 31,859.00 | 41,597.91 | 91.07 | Buy | No |
| Jejurikar Shailesh | 04/29/2024 | 31,000.00 | 9,738.91 | 162.90 | Sell | No |
| Jejurikar Shailesh | 04/29/2024 | 31,000.00 | 40,738.91 | 91.07 | Buy | No |
| Purushothaman Balaji | 04/22/2024 | 28,369.00 | 11,507.08 | 161.49 | Sell | No |
| Purushothaman Balaji | 04/22/2024 | 28,369.00 | 39,876.08 | 80.29 | Buy | No |
| Keith R. Alexandra | 04/21/2024 | 855.00 | 4,003.55 | 158.50 | Sell | No |
| Biggs M. Brett | 03/11/2024 | 155.00 | 1,879.73 | n/a | Buy | No |
Procter Gamble Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Procter & Gamble Co. | 3.68 | 2.43 | USD |
| 2022 | Procter & Gamble Co. | 3.52 | 2.45 | USD |
| 2021 | Procter & Gamble Co. | 3.24 | 2.40 | USD |
| 2020 | Procter & Gamble Co. | 3.03 | 2.53 | USD |
| 2019 | Procter & Gamble Co. | 2.90 | 2.64 | USD |
| 2018 | Procter & Gamble Co. | 2.79 | 3.57 | USD |
| 2017 | Procter & Gamble Co. | 2.70 | 3.10 | USD |
| 2016 | Procter & Gamble Co. | 2.66 | 3.14 | USD |
| 2015 | Procter & Gamble Co. | 2.59 | 3.32 | USD |
| 2014 | Procter & Gamble Co. | 2.45 | 3.12 | USD |
| 2013 | Procter & Gamble Co. | 2.29 | 2.97 | USD |
| 2012 | Procter & Gamble Co. | 2.14 | 3.49 | USD |
| 2011 | Procter & Gamble Co. | 1.97 | 3.10 | USD |
| 2010 | Procter & Gamble Co. | 1.80 | 3.00 | USD |
| 2009 | Procter & Gamble Co. | 1.64 | 3.21 | USD |
| 2008 | Procter & Gamble Co. | 1.45 | 2.38 | USD |
| 2007 | Procter & Gamble Co. | 1.28 | 2.09 | USD |
| 2006 | Procter & Gamble Co. | 1.15 | 2.07 | USD |
| 2005 | Procter & Gamble Co. | 1.03 | 1.86 | USD |
| 2004 | Procter & Gamble Co. | 0.93 | 1.72 | USD |
| 2003 | Procter & Gamble Co. | 0.82 | 1.84 | USD |
| 2002 | Procter & Gamble Co. | 0.76 | 1.70 | USD |
| 2001 | Procter & Gamble Co. | 0.70 | 2.19 | USD |
| 2000 | Procter & Gamble Co. | 0.64 | 2.26 | USD |
| 1999 | Procter & Gamble Co. | 0.57 | 1.29 | USD |
*Yield of the Respective Date
Procter & Gamble Co. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.373 USD | Q4 2024 Earnings Release | 07/30/2024 |
| Earnings Report | 1.938 USD | Q1 2025 Earnings Release | 10/16/2024 |
| Earnings Report | 1.972 USD | Q2 2025 Earnings Release | 01/22/2025 |
| Earnings Report | 1.559 USD | Q3 2025 Earnings Release | 04/18/2025 |
| Earnings Report | 1.492 USD | Q4 2025 Earnings Release | 08/05/2025 |
Procter & Gamble Co. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | - | Q3 2024 Earnings Release | 04/19/2024 |
| Press Conference | - | - | 07/28/2023 |
Procter & Gamble Profile
Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Procter & Gamble Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.94 |
| The Vanguard Group, Inc. | 9.53 |
| Vanguard Group, Inc. (Subfiler) | 9.05 |
| State Street Corp. | 4.34 |
| Vanguard Total Stock Market ETF | 3.15 |
| Vanguard 500 Index Fund | 2.56 |
| BlackRock Fund Advisors | 2.49 |
| BlackRock Institutional Trust Co. NA | 2.17 |
| Geode Capital Management LLC | 2.08 |
| Wellington Management Co. LLP | 1.41 |
| Fidelity 500 Index Fund | 1.21 |
| Norges Bank (13F) | 1.14 |
| Government Pension Fund - Global (The) | 1.12 |
| iShares Core S&P 500 ETF | 1.02 |
| Morgan Stanley Smith Barney LLC | 0.89 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Procter & Gamble Management
| Name | Job |
|---|---|
| Jon R. Moeller | Chairman, President & Chief Executive Officer |
| Matthew W. Janzaruk | Chief Accounting Officer & Senior Vice President |
| Kirti Singh | Chief Analytics, Insights & Media Officer |
| Marc S. Pritchard | Chief Brand Officer |
| Damon Jones | Chief Communications Officer |
| Philip J. Duncan | Chief Design Officer |
| Kristine Decker | Chief Equality & Inclusion Officer |
| Shelly McNamara | Chief Equality & Inclusion Officer |
| Ken K. Patel | Chief Ethics & Compliance Officer |
| Fatima Francisco | Chief Executive Officer-Baby & Feminine Care |
| R. Alexandra Keith | Chief Executive Officer-Beauty |
| Andre Schulten | Chief Financial Officer |
| Bala Purushothaman | Chief Human Resources Officer |
| Vittorio Cretella | Chief Information Officer |
| Shailesh G. Jejurikar | Chief Operating Officer |
| Luc Reynaert | Chief Product Supply Officer |
| Victor Aguilar | Chief Research, Development & Innovation Officer |
| Mindy Sherwood | Chief Sales Officer & President-Global Walmart |
| Virginie Helias | Chief Sustainability Officer |
| Brett M. Biggs | Director |
| Joe Stegbauer | General Counsel, SVP-Corporate & Global Business |
| Amy L. Chang | Independent Director |
| Debra L. Lee | Independent Director |
| Robert Jones Portman | Independent Director |
| Ashley A. McEvoy | Independent Director |
| Bertrand-Marc Allen | Independent Director |
| Christine M. McCarthy | Independent Director |
| Rajesh Subramaniam | Independent Director |
| Patricia Ann Woertz | Independent Director |
| Christopher J. Kempczinski | Independent Director |
| Terry J. Lundgren | Independent Director |
| Sheila Bonini | Independent Director |
| John T. Chevalier | Investor Relations Contact |
| Joseph Jimenez | Lead Independent Director |
| Monica Turner | President-North America |
| Gagan Sawhney | Regional CFO-Middle East & Africa |
| Susan Street Whaley | Secretary & Chief Legal Officer |
| Namrata P Patel | Senior Vice President-Product Supply |
